Herpes simplex infectious disease
MONDO:0004609A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)
Also known as: Simplexvirus caused disease or disorder, Simplexvirus disease or disorder, Simplexvirus infectious disease, herpes simplex, herpes simplex complex, herpes simplex infection, herpes simplex viral infection
38 clinical trials for this condition and its sub-types, 15 tagged with Herpes simplex infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Herpes simplex infectious disease
-
Genital herpes 8 trials
2 sub-types
-
Herpes simplex type 2 infectious disease 5 trials · 8 incl. sub-types
2 sub-types
-
Herpes labialis 5 trials
2 sub-types
-
2 sub-types
-
Herpes simplex virus keratitis 1 trial · 4 incl. sub-types
2 sub-types
- Endotheliitis 2 trials
- Stromal keratitis 1 trial
-
Herpes simplex encephalitis 2 trials
-
Herpes simplex dermatitis 0 trials
-
Herpetic whitlow 0 trials
-
Could a vaccine finally stop the 'Kissing Disease'?
Vaccine CompletedThis study tested a new vaccine designed to prevent Epstein-Barr virus (EBV) infection, which causes most cases of infectious mononucleosis (mono). Twenty-five healthy adults aged 18 to 25 who had never been infected with EBV received either the vaccine or a placebo. The goal was…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New hope for Drug-Resistant herpes in vulnerable patients
Disease control CompletedThis study tested a new oral drug called pritelivir against standard treatments (foscarnet, cidofovir, or imiquimod) for herpes infections that no longer respond to acyclovir. It involved 158 immunocompromised participants, such as those with HIV or organ transplants. The goal wa…
Phase 3 • Sponsor: AiCuris Anti-infective Cures AG • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New shot aims to tame genital herpes outbreaks
Disease control CompletedThis study tested an experimental immunotherapy for herpes simplex virus (HSV) in 505 people. In the first part, healthy adults aged 18-40 received different vaccine-like formulations to check safety. In the second part, adults aged 18-60 with recurrent genital herpes got the tre…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 26, 2026 14:33 UTC
-
AI boosts skin diagnosis accuracy in small trial
Diagnosis CompletedThis completed study tested whether an AI device could help 16 doctors (10 general practitioners and 6 dermatologists) more accurately diagnose 13 different skin conditions, including melanoma, psoriasis, and acne. The doctors reviewed 29 medical images, first giving a diagnosis …
Sponsor: AI Labs Group S.L • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
New vaginal insert could block HIV and herpes – early trial underway
Prevention CompletedThis early-stage trial tested a vaginal insert containing two anti-HIV drugs (tenofovir alafenamide and elvitegravir) in 68 healthy women. The insert was used daily for 3 days then every other day for 14 days. The goal was to check safety and measure drug levels in the body, as a…
Phase 1 • Sponsor: Eastern Virginia Medical School • Aim: Prevention
Last updated Jun 26, 2026 13:00 UTC
-
New study tests oral antiviral for newborns exposed to herpes
Knowledge-focused CompletedThis Phase 1 study tested different doses of the oral antiviral drug valacyclovir in 17 newborns whose mothers had genital herpes. The goal was to find a dose that gives similar drug levels in the blood as the standard IV treatment. Researchers measured how the drug was processed…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC